By discovering retinal cell subgroups in mice, researchers hope to pinpoint an optimal cell type for transplantation to restore vision in blinding conditions

New multimodal imaging study uncovers mechanisms that may help explain persistent depressive symptoms and inform personalized treatments

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq^®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The application is supported by findings from the phase III Alliance ATOMIC (A021502) trial, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, and the German group Arbeitsgemeinschaft Internistische Onkologie (AIO). The study demonstrated that patients experienced significantly improved outcomes when atezolizumab was added to standard chemotherapy following surgery.

A study led by researchers at UC Riverside, the University of Connecticut, Brown University, UCLA, and Fordham University highlights the importance of rigorous participant verification procedures in online health research, particularly when studies recruit hardly reached populations and offer compensation for participation.